Merck & Co. (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name ...

4Q Earnings: $3.7 billion (loss of $1.2 billion 4Q23) FY Earnings: $17.1 billion (earnings were $365 million FY23) ...

After their advanced kidney tumors were surgically removed, nine patients were protected from the cancer returning thanks to ...

Here are seven attractively valued dividend stocks investors can bet on for the long term, according to Bank of America ...

Financial writer advises caution on investing in Merck & Co., Inc. due to negative sentiment and potential price declines. Click for more on MRK Q4 earnings.

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Merck & Co.'s heavy reliance on its cancer drug Keytruda, which accounts for nearly half of the company's revenue, is raising investor concerns as the drug's patent expiration approaches in 2028, The ...

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

Investors have taken to punishing pharma companies that appear unable to gauge demand for their top products. Consider Pfizer. The company’s inability to accurately project demand for its Covid-19 ...

Merck & Co. (MRK) stock lost over 9% yesterday on announcing a temporary shipment halt of its Gardasil vaccine to China. The ...

Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.

Pharma giant Merck on Tuesday announced in its earnings report that it would halt all shipments of HPV drug Gardasil to China ...